A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia

Human Molecular Genetics

Volumn 21, Issue 26, 2012, Pages 5443-5455

  Jin, Min ^a   Yu, Ying ^b   Qi, Huabing ^a   Xie, Yangli ^a   Su, Nan ^a   Wang, Xiaofeng ^a   Tan, Qiaoyan ^a   Luo, Fengtao ^a   Zhu, Ying ^a   Wang, Quan ^a   Du, Xiaolan ^a   Xian, Cory J ^c   Liu, Peng ^a   Huang, Haiyang ^a   Shen, Yue ^a   Deng, Chu Xia ^d   Chen, Di ^e   Chen, Lin ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHONGQING UNIVERSITY OF TECHNOLOGY   (China)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHILIN A; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE; PEPTIDE DERIVATIVE; PEPTIDE P3; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BONE GROWTH; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHONDROGENESIS; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME ACTIVITY; FEMALE; MALE; METATARSAL BONE; MOUSE; NONHUMAN; PEPTIDE LIBRARY; PHAGE DISPLAY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; SURVIVAL RATE; THANATOPHORIC DWARFISM;

ANIMALS; CARRIER PROTEINS; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CLONING, MOLECULAR; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEK293 CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, KNOCKOUT; PEPTIDE LIBRARY; PEPTIDES; PHENOTYPE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION; SKULL; THANATOPHORIC DYSPLASIA;

MUS;

EID: 84870849268     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/dds390     Document Type: Article

References (59)

1. Xian, C.J. (2007) Roles of epidermal growth factor family in the regulation of postnatal somatic growth. Endocr. Rev., 28, 284-296.
2. Shiang, R., Thompson, L.M., Zhu, Y.Z., Church, D.M., Fielder, T.J., Bocian, M., Winokur, S.T. and Wasmuth, J.J. (1994) Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell, 78, 335-342.
3. Horton, W.A. (1997) Fibroblast growth factor receptor 3 and the human chondrodysplasias. Curr. Opin. Pediatr., 9, 437-442.
4. Bonaventure, J., Rousseau, F., Legeai-Mallet, L., Le Merrer, M., Munnich, A. and Maroteaux, P. (1996) Common mutations in the fibroblast growth factor receptor 3 (FGFR 3) gene account for achondroplasia, hypochondroplasia, and thanatophoric dwarfism. Am. J. Med. Genet., 63, 148-154.
5. Rousseau, F., el Ghouzzi, V., Delezoide, A.L., Legeai-Mallet, L., Le Merrer, M., Munnich, A. and Bonaventure, J. (1996) Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1). Hum. Mol. Genet., 5, 509-512.
6. Toydemir, R.M., Brassington, A.E., Bayrak-Toydemir, P., Krakowiak, P.A., Jorde, L.B., Whitby, F.G., Longo, N., Viskochil, D.H., Carey, J.C. and Bamshad, M.J. (2006) A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome. Am. J. Hum. Genet., 79, 935-941.
7. Naski, M.C., Colvin, J.S., Coffin, J.D. and Ornitz, D.M. (1998) Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. Development, 125, 4977-4988.
8. Chen, L., Adar, R., Yang, X., Monsonego, E.O., Li, C., Hauschka, P.V., Yayon, A. and Deng, C.X. (1999) Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis. J. Clin. Invest., 104, 1517-1525.
9. Ornitz, D.M. and Marie, P.J. (2002) FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes. Dev., 16, 1446-1465.
10. Li, C., Chen, L., Iwata, T., Kitagawa, M., Fu, X.Y. and Deng, C.X. (1999) A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors. Hum. Mol. Genet., 8, 35-44.
11. Su, W.C., Kitagawa, M., Xue, N., Xie, B., Garofalo, S., Cho, J., Deng, C., Horton, W.A. and Fu, X.Y. (1997) Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. Nature, 386, 288-292.
12. Sahni, M., Ambrosetti, D.C., Mansukhani, A., Gertner, R., Levy, D. and Basilico, C. (1999) FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes. Dev., 13, 1361-1366.
13. Murakami, S., Balmes, G., McKinney, S., Zhang, Z., Givol, D. and de Crombrugghe, B. (2004) Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype. Genes. Dev., 18, 290-305.
14. Ornitz, D.M. (2000) FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays, 22, 108-112.
15. Qing, J., Du, X., Chen, Y., Chan, P., Li, H., Wu, P., Marsters, S., Stawicki, S., Tien, J., Totpal, K. et al. (2009) Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J. Clin. Invest., 119, 1216-1229.
16. Shimizu, A., Tada, K., Shukunami, C., Hiraki, Y., Kurokawa, T., Magane, N. and Kurokawa-Seo, M. (2001) A novel alternatively spliced fibroblast growth factor receptor 3 isoform lacking the acid box domain is expressed during chondrogenic differentiation of ATDC5 cells. J. Biol. Chem., 276, 11031-11040.
17. Altaf, F.M., Hering, T.M., Kazmi, N.H., Yoo, J.U. and Johnstone, B. (2006) Ascorbate-enhanced chondrogenesis of ATDC5 cells. Eur. Cell Mater., 12, 64-69; discussion 69-70.
18. Iwata, T., Chen, L., Li, C., Ovchinnikov, D.A., Behringer, R.R., Francomano, C.A. and Deng, C.X. (2000) A neonatal lethal mutation in FGFR3 uncouples proliferation and differentiation of growth plate chondrocytes in embryos. Hum. Mol. Genet., 9, 1603-1613.
19. Rousseau, F., Bonaventure, J., Legeai-Mallet, L., Pelet, A., Rozet, J.M., Maroteaux, P., Le Merrer, M. and Munnich, A. (1994) Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature, 371, 252-254.
20. Bellus, G.A., Hefferon, T.W., Ortiz de Luna, R.I., Hecht, J.T., Horton, W.A., Machado, M., Kaitila, I., McIntosh, I. and Francomano, C.A. (1995) Achondroplasia is defined by recurrent G380R mutations of FGFR3. Am. J. Hum. Genet., 56, 368-373.
21. Passos-Bueno, M.R., Wilcox, W.R., Jabs, E.W., Sertie, A.L., Alonso, L.G. and Kitoh, H. (1999) Clinical spectrum of fibroblast growth factor receptor mutations. Hum. Mutat., 14, 115-125.
22. Tavormina, P.L., Shiang, R., Thompson, L.M., Zhu, Y.Z., Wilkin, D.J., Lachman, R.S., Wilcox, W.R., Rimoin, D.L., Cohn, D.H. and Wasmuth, J.J. (1995) Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat. Genet., 9, 321-328.
23. Shohat, M., Tick, D., Barakat, S., Bu, X., Melmed, S. and Rimoin, D.L. (1996) Short-term recombinant human growth hormone treatment increases growth rate in achondroplasia. J. Clin. Endocrinol. Metab., 81, 4033-4037.
24. Stamoyannou, L., Karachaliou, F., Neou, P., Papataxiarchou, K., Pistevos, G. and Bartsocas, C.S. (1997) Growth and growth hormone therapy in children with achondroplasia: a two-year experience. Am. J. Med. Genet., 72, 71-76.
25. Weber, G., Prinster, C., Meneghel, M., Russo, F., Mora, S., Puzzovio, M., Del Maschio, M. and Chiumello, G. (1996) Human growth hormone treatment in prepubertal children with achondroplasia. Am. J. Med. Genet., 61, 396-400.
26. Aldegheri, R. and Dall'Oca, C. (2001) Limb lengthening in short stature patients. J. Pediatr. Orthop. B, 10, 238-247.
27. Aldegheri, R., Trivella, G., Renzi-Brivio, L., Tessari, G., Agostini, S. and Lavini, F. (1988) Lengthening of the lower limbs in achondroplastic patients. A comparative study of four techniques. J. Bone Joint Surg. Br., 70, 69-73.
28. Aviezer, D., Golembo, M. and Yayon, A. (2003) Fibroblast growth factor receptor-3 as a therapeutic target for Achondroplasia-genetic short limbed dwarfism. Curr. Drug Targets, 4, 353-365.
29. Yasoda, A., Komatsu, Y., Chusho, H., Miyazawa, T., Ozasa, A., Miura, M., Kurihara, T., Rogi, T., Tanaka, S., Suda, M. et al. (2004) Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. Nat. Med., 10, 80-86.
30. Ozasa, A., Komatsu, Y., Yasoda, A., Miura, M., Sakuma, Y., Nakatsuru, Y., Arai, H., Itoh, N. and Nakao, K. (2005) Complementary antagonistic actions between C-type natriuretic peptide and the MAPK pathway through FGFR-3 in ATDC5 cells. Bone, 36, 1056-1064.
31. Chen, L., Li, C., Qiao, W., Xu, X. and Deng, C. (2001) A Ser(365)-Cys mutation of fibroblast growth factor receptor 3 in mouse downregulates Ihh/PTHrP signals and causes severe achondroplasia. Hum. Mol. Genet., 10, 457-465.
32. Ogawa, T., Yamagiwa, H., Hayami, T., Liu, Z., Huang, K.Y., Tokunaga, K., Murai, T. and Endo, N. (2002) Human PTH (1-34) induces longitudinal bone growth in rats. J. Bone Miner. Metab., 20, 83-90.
33. Ueda, K., Yamanaka, Y., Harada, D., Yamagami, E., Tanaka, H. and Seino, Y. (2007) PTH has the potential to rescue disturbed bone growth in achondroplasia. Bone, 41, 13-18.
34. Shukla, V., Coumoul, X., Wang, R.H., Kim, H.S. and Deng, C.X. (2007) RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis. Nat. Genet., 39, 1145-1150.
35. Hamman, J.H., Enslin, G.M. and Kotze, A.F. (2005) Oral delivery of peptide drugs: barriers and developments. BioDrugs, 19, 165-177.
36. Gomez-Orellana, I. (2005) Strategies to improve oral drug bioavailability. Expert Opin. Drug Deliv., 2, 419-433.
37. Joshi, M.B., Gam, A.A., Boykins, R.A., Kumar, S., Sacci, J., Hoffman, S.L., Nakhasi, H.L. and Kenney, R.T. (2001) Immunogenicity of well-characterized synthetic Plasmodium falciparum multiple antigen peptide conjugates. Infect. Immun., 69, 4884-4890.
38. Chien, R.N., Liaw, Y.F., Chen, T.C., Yeh, C.T. and Sheen, I.S. (1998) Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology, 27, 1383-1387.
39. Barry, M.A., Dower, W.J. and Johnston, S.A. (1996) Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. Nat. Med., 2, 299-305.
40. Scott, J.K. and Smith, G.P. (1990) Searching for peptide ligands with an epitope library. Science, 249, 386-390.
41. Legeai-Mallet, L., Benoist-Lasselin, C., Delezoide, A.L., Munnich, A. and Bonaventure, J. (1998) Fibroblast growth factor receptor 3 mutations promote apoptosis but do not alter chondrocyte proliferation in thanatophoric dysplasia. J. Biol. Chem., 273, 13007-13014.
42. L'Hote, C.G. and Knowles, M.A. (2005) Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp. Cell Res., 304, 417-431.
43. Su, N., Du, X. and Chen, L. (2008) FGF signaling: its role in bone development and human skeleton diseases. Front. Biosci., 13, 2842-2865.
44. Deng, C., Wynshaw-Boris, A., Zhou, F., Kuo, A. and Leder, P. (1996) Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell, 84, 911-921.
45. Colvin, J.S., Bohne, B.A., Harding, G.W., McEwen, D.G. and Ornitz, D.M. (1996) Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat. Genet., 12, 390-397.
46. Chesi, M., Nardini, E., Brents, L.A., Schrock, E., Ried, T., Kuehl, W.M. and Bergsagel, P.L. (1997) Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat. Genet., 16, 260-264.
47. Intini, D., Baldini, L., Fabris, S., Lombardi, L., Ciceri, G., Maiolo, A.T. and Neri, A. (2001) Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). Br. J. Haematol., 114, 362-364.
48. Cappellen, D., De Oliveira, C., Ricol, D., de Medina, S., Bourdin, J., Sastre-Garau, X., Chopin, D., Thiery, J.P. and Radvanyi, F. (1999) Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Genet., 23, 18-20.
49. Hernandez, S., de Muga, S., Agell, L., Juanpere, N., Esgueva, R., Lorente, J.A., Mojal, S., Serrano, S. and Lloreta, J. (2009) FGFR3 mutations in prostate cancer: association with low-grade tumors. Mod. Pathol., 22, 848-856.
50. Muenke, M., Gripp, K.W., McDonald-McGinn, D.M., Gaudenz, K., Whitaker, L.A., Bartlett, S.P., Markowitz, R.I., Robin, N.H., Nwokoro, N., Mulvihill, J.J. et al. (1997) A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome. Am. J. Hum. Genet., 60, 555-564.
51. Hafner, C., van Oers, J.M., Vogt, T., Landthaler, M., Stoehr, R., Blaszyk, H., Hofstaedter, F., Zwarthoff, E.C. and Hartmann, A. (2006) Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J. Clin. Invest., 116, 2201-2207.
52. Hafner, C., Stoehr, R., van Oers, J.M., Zwarthoff, E.C., Hofstaedter, F., Landthaler, M., Hartmann, A. and Vogt, T. (2009) FGFR3 and PIK3CA mutations are involved in the molecular pathogenesis of solar lentigo. Br. J. Dermatol., 160, 546-551.
53. Goriely, A., Hansen, R.M., Taylor, I.B., Olesen, I.A., Jacobsen, G.K., McGowan, S.J., Pfeifer, S.P., McVean, G.A., Rajpert-De Meyts, E. and Wilkie, A.O. (2009) Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. Nat. Genet., 41, 1247-1252.
54. Su, N., Sun, Q., Li, C., Lu, X., Qi, H., Chen, S., Yang, J., Du, X., Zhao, L., He, Q. et al. (2010) Gain-of-function mutation in FGFR3 in mice leads to decreased bone mass by affecting both osteoblastogenesis and osteoclastogenesis. Hum. Mol. Genet., 19, 1199-1210.
55. Shukunami, C., Shigeno, C., Atsumi, T., Ishizeki, K., Suzuki, F. and Hiraki, Y. (1996) Chondrogenic differentiation of clonal mouse embryonic cell line ATDC5 in vitro: differentiation-dependent gene expression of parathyroid hormone (PTH)/PTH-related peptide receptor. J. Cell Biol., 133, 457-468.
56. Hoogendam, J., Parlevliet, E., Miclea, R., Lowik, C.W., Wit, J.M. and Karperien, M. (2006) Novel early target genes of parathyroid hormone-related peptide in chondrocytes. Endocrinology, 147, 3141-3152.
57. Farndale, R.W., Buttle, D.J. and Barrett, A.J. (1986) Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim. Biophys. Acta, 883, 173-177.
58. Lakso, M., Pichel, J.G., Gorman, J.R., Sauer, B., Okamoto, Y., Lee, E., Alt, F.W. and Westphal, H. (1996) Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. Proc. Natl Acad. Sci. USA, 93, 5860-5865.
59. McLeod, M.J. (1980) Differential staining of cartilage and bone in whole mouse fetuses by Alcian blue and alizarin red S. Teratology, 22, 299-301.